EFFICACY AND TOLERABILITY OF BRODIMOPRIM IN PEDIATRIC INFECTIONS

Brodimoprim is along acting broad spectrum antibacterial agent. It is a new selective inhibitor of: bacterial dihydrofolate reductase, struc turally related to trimethoprim. The aim of the present study was to i nvestigate the efficacy and tolerability of brodimoprim (10 mg/kg on t he first day, 5 mg/kg/die onward) in the treatment of upper respirator y tract infections in children (age range: 2-14 years). This open grou p comparative study was performed either in 68 children affected by ba cterial pharyngotonsillitis (37 treated with brodimoprim, 31 with eryt hromycin 560 mg/kg/8 hours) or in 50 patients affected by otitis media (25 treated with brodimoprim, 25 with amoxicillin/clavulanic acid 50 mg/kg/12 hours) or in 52 patients affected by acute sinusitits (25 tre ated with brodimoprim, 27 with amoxicillin/clavulanic acid 50 mg/kg/12 hours). All patients were clinically evaluated before admission, duri ng the trial and 48 hours after the last dose of antibiotic. At the sa me time blood and secretion samples were collected for hematology/bioc hemistry and microbiological assays. A total of 170 subjects were trea ted and 141 patients demonstrated a clinical recovery/improvement foll owing the treatment period, with approximately the same recovery rate (83%) among the groups. The bacteriological response was evaluated in 169 subjects. Eradication of pathogens was docu mented in 27 subjects treated with brodimoprim and 28 with erythromycin in the pharyngotonsi llitis group, in 22 subjects treated with brodimoprim and 16 with amox icillin/clavulanic acid in the otitis group and in 17 subjects treated with brodimoprim and 20 with amoxcillin/clavulanic acid in the sinusi tis group. The overall eradication in brodimoprim treated patients was 77% in comparison with 76% of eradication obtained in the control gro ups.